Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lirafugratinib→

Lirafugratinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2549174-42-5
Molecular formula
C28H24FN7O2
Molecular weight
509.54 g/mol
Drug class
Selective fibroblast growth factor receptor (FGFR) kinase inhibitortargeted antineoplastic agent
Mechanism of action
Lirafugratinib is an oral, selective FGFR inhibitor that targets FGFR2 alterations driving tumour growth. It inhibits FGFR2 kinase signalling, reducing downstream pathway activation in FGFR2 fusion- or rearrangement-positive cholangiocarcinoma. The product label describes it as a kinase inhibitor.
Indications / reported uses
  • Treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harbouring an FGFR2 gene fusion or other rearrangement, under the US LYRFIGTU product label (approved September 23, 2026).

Sources: https://www.fda.gov/drugs/cancer-approvals/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic · https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220425Orig1s000lbl.pdf

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lirafugratinib Environmental Risk Assessment (ERA) (the Lirafugratinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.